PUMA
16.5.2023 15:41:29 CEST | Business Wire | Press release
Global sports company PUMA and absorbent apparel brand, Modibodi® are launching the third drop of their best-selling active period underwear range; combining Modibodi’s unique, patented technology with world-class expertise from PUMA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005712/en/
Global sports company PUMA and absorbent apparel brand, Modibodi® are launching the third drop of their best-selling active period underwear range; combining Modibodi’s unique, patented technology with world-class expertise from PUMA. (Photo: Business Wire)
Ever worn white or tight sports uniforms that made you feel uncomfortable about leaking when playing on your period? Or felt exposed in sportswear that left the wings and strings of your disposables on display?
From archaic sports codes to national team uniform fines, athletes are often told to keep playing on their period, when what they’re told to wear makes it extremely uncomfortable and anxiety-inducing.
But that’s about to change. Enter PUMA x Modibodi active period underwear. The new PUMA x Modibodi active period underwear is in league of its own – made for maximum protection and performance on and off the court, field or gym floor. The collection combines soft, breathable fabrics that stretch and move with your body with Modibodi’s concealed absorbent lining, proven to keep you free from leaks, sweat and discharge.
Modibodi Ambassador and Brisbane City FC Captain, Jamilla Riley, says: “As someone who menstruates and plays soccer in a white uniform, I can attest to the discomfort and anxiety that combination can create, particularly when you are young. You spend your time shamed by the fear of leaks, and it can take all your mental strength to refocus on the game at hand. That’s why I’m such an advocate of the new PUMA x Modibodi active period undies. The designs not only bring some much-needed innovation to the sportswear market, but they also help support your menstruating body so you can play without fear of leaking and kick some goals. Who knew playing on your period could be this comfy It’s liberating!”
Modibodi Design and Innovation Director, Charissa Lanham says: “We wanted to destigmatise the challenges of menstruating whilst competing and show athletes a new world in which they can feel confident and supported to play while they bleed. We worked with PUMA to design a range of active period underwear that utilises Modibodi’s world-first patented technology which includes a leak-proof barrier layer for secure protection; meaning athletes can focus on their game, not their period.”
A workout staple, the PUMA x Modibodi collection absorbs fast and offers peace of mind on the pitch by replacing the need for disposable pads, liners and tampons as you play. The super slim, absorbent black lining is designed to help prevent leaks and unwanted stains. Featuring 3 layers of built-in technology that can hold up to 15ml (or 2-3 tampons) without staining your activewear or sports uniform.
To ensure comfort, each design is crafted from 82% recycled material, includes a wider logo waist band for security whilst playing and an aerated mesh side panel to maximise airflow. Modibodi’s proprietary Modifier Technology™ then works to wick moisture and sweat, locking away fluid and odour to keep you feeling fresh and dry.
Available in a two-colour ways Black/Platinum Grey and Black/Green, the collection consists of 3 styles in a range of Light-Moderate to Moderate-Heavy absorbencies, making them ideal to absorb your period and sweat, and keep you fresh and dry, way beyond the final whistle.
The PUMA x Modibodi collection is available online at modibodi.com.
The PUMA x Modibodi collection is available in selected stores and online at puma.com and modibodi.com.
PUMA |
PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.
MODIBODI |
Since 2013, Modibodi® has had one goal – to make changing the world as easy as changing your underwear. What they didn’t realise, is that in doing so, they’d change the lives of their customers along the way.
Life-changing is the number one phrase heard from Modibodi customers. It’s a language woven into the brand’s DNA and sits firmly at the heart of what they do. Having made a name for itself globally, designing confidence-shaping, confidence-creating, planet-sustaining, life-changing apparel, Modibodi® offers comfort from periods, pee and bodily leaks, and champions conversations and initiatives that allow people to live more comfortably in themselves.
Designed with compassion and offering a sustainable solution to disposable products, Modibodi uses proprietary innovation and patented technology to ensure each and every one of their designs is market leading, saving billions of single-use disposable hygiene products from ending up in landfill.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005712/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
